SCHEMBL23527268

SCHEMBL23527268

O=C(CSc1nnc(-c2ccccc2)[nH]1)c1ccc(O)cc1O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALPL P05186 2/20 0.64
▸ ALDH1A1 P00352 3/20 0.59
▸ KDM4E B2RXH2 2/20 0.59
▸ STAT1 P42224 1/20 0.59
▸ KMT2A Q03164 10/20 0.54
▸ MAPT P10636 4/20 0.52
▸ POLB P06746 4/20 0.51
▸ GAA P10253 3/20 0.51
▸ NPC1 O15118 2/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ MEN1 O00255 8/20 0.49
▸ CNKSR1 Q969H4 1/20 0.41
▸ HSP90AB1 P08238 2/20 0.40
▸ LMNA P02545 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ ALPI P09923 1/20 0.40
▸ ALPG P10696 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ ALOX12 P18054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31140793 1.00 ALPL (0.64) ALPLALDH1A1KDM4ESTAT1KMT2A
SCHEMBL31140790 0.80 NPC1 (0.55) ALPLALDH1A1KMT2AMAPTPOLB
SCHEMBL23527347 0.80 NPC1 (0.55) ALPLALDH1A1KMT2AMAPTPOLB
SCHEMBL31140773 0.80 MAPT (0.58) ALPLALDH1A1KDM4EKMT2AMAPT
SCHEMBL23527284 0.80 ALPG (0.63) ALPLALDH1A1KDM4EKMT2AMAPT
SCHEMBL23527069 0.80 MAPT (0.58) ALPLALDH1A1KDM4EKMT2AMAPT
SCHEMBL23527338 0.79 PTGES (0.59) ALDH1A1KDM4EKMT2AMAPTGAA
SCHEMBL31140794 0.78 ALDH1A1 (0.52) ALDH1A1KDM4EKMT2AMAPTPOLB
SCHEMBL23527203 0.78 ALDH1A1 (0.52) ALDH1A1KDM4EKMT2AMAPTPOLB
SCHEMBL23527345 0.77 PTGES (0.53) ALPLALDH1A1KDM4EKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4075980-B1 SUBSTITUTED 1,2, 4-TRIAZOLES AND METHODS OF USE STINGINN LLC (US) 2025-07-23 — — EP disclosed
US-20210188786-A1 SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE STINGINN LLC (US) 2021-06-24 — — US disclosed
US-20210188786-A1 SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE STINGINN LLC (US) 2021-06-24 — — US disclosed
WO-2021127282-A1 SUBSTITUTED 1,2, 4-TRIAZOLES AND METHODS OF USE STINGINN LLC (US) 2021-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188786-A1 SUBSTITUTED 1,2,4-TRIAZOLES AND METHODS OF USE STING1, IRF3, CGAS ALPL 4003/4885ALDH1A1 3318/4885KDM4E 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback